Parkman Healthcare Partners LLC increased its position in shares of QIAGEN N.V. (NYSE:QGEN - Free Report) by 29.7% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 359,644 shares of the company's stock after acquiring an additional 82,372 shares during the period. QIAGEN makes up about 1.7% of Parkman Healthcare Partners LLC's investment portfolio, making the stock its 23rd largest position. Parkman Healthcare Partners LLC owned approximately 0.16% of QIAGEN worth $14,440,000 at the end of the most recent quarter.
A number of other hedge funds have also recently bought and sold shares of the company. Exchange Traded Concepts LLC grew its holdings in QIAGEN by 2.3% during the first quarter. Exchange Traded Concepts LLC now owns 17,825 shares of the company's stock worth $716,000 after acquiring an additional 395 shares during the period. SVB Wealth LLC acquired a new position in shares of QIAGEN in the 1st quarter valued at $31,000. Walleye Trading LLC boosted its position in shares of QIAGEN by 14.6% in the 1st quarter. Walleye Trading LLC now owns 7,367 shares of the company's stock valued at $296,000 after purchasing an additional 936 shares during the period. Cetera Investment Advisers boosted its position in shares of QIAGEN by 14.4% in the 4th quarter. Cetera Investment Advisers now owns 11,297 shares of the company's stock valued at $505,000 after purchasing an additional 1,418 shares during the period. Finally, GAMMA Investing LLC boosted its position in shares of QIAGEN by 93.9% in the 1st quarter. GAMMA Investing LLC now owns 2,943 shares of the company's stock valued at $118,000 after purchasing an additional 1,425 shares during the period. 70.00% of the stock is owned by institutional investors and hedge funds.
QIAGEN Stock Down 1.1%
QIAGEN stock traded down $0.50 during mid-day trading on Tuesday, hitting $47.08. The company's stock had a trading volume of 903,884 shares, compared to its average volume of 1,318,712. The firm's 50 day moving average is $48.62 and its 200 day moving average is $44.50. The company has a market cap of $10.47 billion, a PE ratio of 27.82, a price-to-earnings-growth ratio of 2.51 and a beta of 0.64. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.61 and a quick ratio of 1.35. QIAGEN N.V. has a 52-week low of $37.63 and a 52-week high of $51.88.
QIAGEN (NYSE:QGEN - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $0.60 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.60. The firm had revenue of $533.54 million during the quarter, compared to the consensus estimate of $523.97 million. QIAGEN had a return on equity of 14.77% and a net margin of 18.30%.The business's revenue for the quarter was up 7.7% on a year-over-year basis. During the same period in the prior year, the business earned $0.55 EPS. QIAGEN has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. On average, analysts anticipate that QIAGEN N.V. will post 2.26 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of equities analysts recently weighed in on the company. Wall Street Zen lowered QIAGEN from a "strong-buy" rating to a "buy" rating in a research report on Monday, August 11th. Cowen reiterated a "hold" rating on shares of QIAGEN in a research report on Thursday, August 7th. Barclays assumed coverage on QIAGEN in a research report on Tuesday, June 24th. They issued an "overweight" rating and a $55.00 price target for the company. Bank of America increased their price target on QIAGEN from $50.00 to $53.00 and gave the company a "buy" rating in a research report on Thursday, June 26th. Finally, UBS Group increased their price target on QIAGEN from $48.00 to $50.00 and gave the company a "neutral" rating in a research report on Thursday, August 7th. Three research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $49.69.
View Our Latest Stock Analysis on QIAGEN
QIAGEN Company Profile
(
Free Report)
QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.
Recommended Stories
Before you consider Qiagen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Qiagen wasn't on the list.
While Qiagen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
